User login
SAN ANTONIO – Dr. Howard A. Burris III, Dr. William J. Gradishar, and Dr. Hope S. Rugo remark on the implications of the CLEOPATRA trial, in which the addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to an additional 6 months of progression-free survival in patients with HER2-positive metastatic breast cancer, at the 2011 San Antonio Breast Cancer Symposium.
SAN ANTONIO – Dr. Howard A. Burris III, Dr. William J. Gradishar, and Dr. Hope S. Rugo remark on the implications of the CLEOPATRA trial, in which the addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to an additional 6 months of progression-free survival in patients with HER2-positive metastatic breast cancer, at the 2011 San Antonio Breast Cancer Symposium.
SAN ANTONIO – Dr. Howard A. Burris III, Dr. William J. Gradishar, and Dr. Hope S. Rugo remark on the implications of the CLEOPATRA trial, in which the addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to an additional 6 months of progression-free survival in patients with HER2-positive metastatic breast cancer, at the 2011 San Antonio Breast Cancer Symposium.